In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Chemours Company (NYSE: CC) closed at $12.47 up 1.22% from its previous closing price of $12.32. In other words, the price has increased by $1.22 from its previous closing price. On the day, 2.42 million shares were traded. CC stock price reached its highest trading level at $12.63 during the session, while it also had its lowest trading level at $12.19.
Ratios:
For a deeper understanding of Chemours Company’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.88 and its Current Ratio is at 1.71. In the meantime, Its Debt-to-Equity ratio is 14.82 whereas as Long-Term Debt/Eq ratio is at 14.43.
On January 28, 2025, Truist started tracking the stock assigning a Buy rating and target price of $27.
UBS Upgraded its Neutral to Buy on July 09, 2024, whereas the target price for the stock was revised from $28 to $30.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 08 ’25 when Dignam Denise bought 4,068 shares for $12.06 per share. The transaction valued at 49,060 led to the insider holds 191,546 shares of the business.
Gumpel Damian bought 13,400 shares of CC for $123,548 on Jun 02 ’25. The insider now owns 123,879 shares after completing the transaction at $9.22 per share. On Jun 03 ’25, another insider, Gumpel Damian, who serves as the insider of the company, bought 7,822 shares for $9.95 each. As a result, the insider paid 77,828 and bolstered with 131,701 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CC now has a Market Capitalization of 1869152640 and an Enterprise Value of 5677152768. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.32 while its Price-to-Book (P/B) ratio in mrq is 6.27. Its current Enterprise Value per Revenue stands at 0.973 whereas that against EBITDA is 8.615.
Stock Price History:
The Beta on a monthly basis for CC is 1.59, which has changed by -0.42640293 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, CC has reached a high of $22.38, while it has fallen to a 52-week low of $9.13. The 50-Day Moving Average of the stock is -9.11%, while the 200-Day Moving Average is calculated to be -6.26%.
Shares Statistics:
For the past three months, CC has traded an average of 3.03M shares per day and 2814360 over the past ten days. A total of 149.87M shares are outstanding, with a floating share count of 148.77M. Insiders hold about 0.75% of the company’s shares, while institutions hold 94.87% stake in the company. Shares short for CC as of 1763078400 were 13611867 with a Short Ratio of 4.49, compared to 1760486400 on 13517385. Therefore, it implies a Short% of Shares Outstanding of 13611867 and a Short% of Float of 13.340001.
Dividends & Splits
According to the company, the forward annual dividend rate for CC is 0.51, from 0.675 in the trailing year. Against a Trailing Annual Dividend Yield of 0.054788962. The stock’s 5-year Average Dividend Yield is 4.06.
Earnings Estimates
At present, 7.0 analysts are actively evaluating the performance of Chemours Company (CC) in the stock market.The consensus estimate for the next quarter is $0.13, with high estimates of $0.32 and low estimates of -$0.12.
Analysts are recommending an EPS of between $1.4 and $0.79 for the fiscal current year, implying an average EPS of $1.01. EPS for the following year is $1.84, with 9.0 analysts recommending between $2.15 and $1.46.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $1.34B this quarter.It ranges from a high estimate of $1.4B to a low estimate of $1.3B. As of. The current estimate, Chemours Company’s year-ago sales were $1.36BFor the next quarter, 7 analysts are estimating revenue of $1.44B. There is a high estimate of $1.46B for the next quarter, whereas the lowest estimate is $1.42B.
A total of 9 analysts have provided revenue estimates for CC’s current fiscal year. The highest revenue estimate was $5.88B, while the lowest revenue estimate was $5.77B, resulting in an average revenue estimate of $5.81B. In the same quarter a year ago, actual revenue was $5.78BBased on 9 analysts’ estimates, the company’s revenue will be $6.06B in the next fiscal year. The high estimate is $6.17B and the low estimate is $5.95B.
